COVID-19: Generic version of remdesivir

COVID-19: Generic version of remdesivir launched by Jubilant Life Sciences

Global Pharmaceuticals and Life Sciences company – Jubilant Life Sciences claimed it has launched the generic version of antiviral medicine remdesivir in India for treating COVID-19. The drug is an injectable drug under the brand name ‘JUBI-R’. The drug costs Rs 4,700/vial of 100 mg. Jubilant Life Sciences stated in a declaration that they will make the medicine readily available to over 1,000 healthcare facilities offering COVID-19 treatment.

Jubilant Bhartia Foundation, a not-for-profit organization of the Jubilant Group, is launching programs in India focused on its distribution, in order to raise the accessibility of the drug to patients below the poverty line and also to front-line paramedical staffs. Jubilant Pharma Chairman and MD Shyam S Bhartia and Co-Chairman Hari S Bhartia said in the statement said that we have introduced the product at economical rates as well as strive to make it readily available in adequate amounts to fulfill the high need for the medication in the Indian market and also in other nations.

They included that the firm’s capability to introduce this product in such short timelines highlights the R&D and production capabilities and our continued dedication in giving leading healthcare solutions. Jubliant entered into a non-exclusive licensing contract with Gilead Sciences Inc in May 2020. This contract gave it the right to register, manufacture, and sell the US-based firm’s investigational medicine remdesivir in 127 nations, including India.

See Also
Complete List Of Top 10 Pharmaceutical Companies in India 2020

The statement stated that the firm got authorization to manufacture as well as market remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency situation usage in India for treating severe COVID-19 patients, from the Drug Controller General of India on July 20, 2020. The medicine will certainly need to be administered intravenously in a hospital set up under the guidance of a physician.

The statement further added that Remdesivir is the only antiviral drug that has got Emergency Use Authorization by the United States Food and Drug Administration for treating adults as well as kids hospitalized with serious disease severe COVID-19.

Source

COVID-19: Generic version of remdesivir launched by Jubilant Life Sciences

Author: Sruthi S

Upload your CV to Rasayanika Talent Pool

LEAVE A REPLY

Please enter your comment!
Please enter your name here